Zydus Wellness (531335) Q4 02/03 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 02/03 earnings summary
3 Nov, 2026Executive summary
Sales and other income rose 42% YoY to Rs. 9.13 crore; the year ended with profit after tax of Rs. 93.58 lakh versus Rs. 46.61 lakh.
After covering the prior-year accumulated deficit and proposed dividend, Rs. 21.89 lakh was carried forward as surplus.
Financial highlights
Sales were Rs. 8.86 crore versus Rs. 6.21 crore; total income was Rs. 9.13 crore versus Rs. 6.42 crore.
Profit before tax and exceptional items was Rs. 1.17 crore versus Rs. 54.54 lakh; profit after tax was Rs. 93.58 lakh versus Rs. 46.61 lakh.
Total expenditure increased to Rs. 7.96 crore from Rs. 5.87 crore; it represented 87% of total income versus 84% in the prior year.
Net cash from operating activities was Rs. 1.35 crore; cash and bank balances rose to Rs. 2.41 crore from Rs. 1.23 crore.
Outlook and guidance
Marketing initiatives included improving sales-force effectiveness, rationalizing stockists and strengthening field-selling discipline; these measures reportedly supported operating margins.
A Jaipur branch opened and sales reached new geographies; management cautioned that forward-looking outcomes could differ due to multiple factors.
The tentative FY 2003-04 financial calendar scheduled quarterly results for the last weeks of July, October and January, with FY results in the last week of April.
Latest events from Zydus Wellness
- Sales and EBITDA surged as gross margin expanded and brand growth continued.531335
Q2 26/27 - Sales rose, but FY98 ended with a Rs. 78.8 lakh net loss.531335
Q4 97/98 - Sales surged, but FY99 ended with a Rs 45,36,571 loss before tax.531335
Q4 98/99 - Higher sales and production accompanied a narrower loss, but operating cash flow remained negative.531335
Q4 99/00 - FY02 profit improved as new-product investment positioned the business for growth.531335
Q4 01/02 - Sales more than doubled as profits rose and product expansion broadened.531335
Q4 03/04 - Revenue rose 60.75% as capacity expansion and regional growth plans advanced.531335
Q4 04/05 - Revenue surged 49%, but profit eased amid advertising investment; Nutralite Premium launched.531335
Q4 06/07 - Sales grew 9.12%, profit held near flat, and Cadila Healthcare took a 61.56% stake.531335
Q4 05/06